PAM
CRNX icon

Panagora Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Panagora Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-324
Closed -$5K – 2810
2021
Q1 		$5K Hold
324
– – ﹤0.01% 2570
2020
Q4 		$5K Buy
+324
New +$4.51K ﹤0.01% 2455

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Panagora Asset Management's CRNX Position: Q2 2021 in Review

Panagora Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2021, closing a stake of 324 shares — an estimated $5K sold.

Panagora Asset Management first reported a position in CRNX in Q4 2020 and held it in 2 quarters. The position peaked at $5K in Q1 2021. 83 funds tracked by Wall St. Rank hold CRNX as of Q2 2021.

  • Panagora Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Panagora Asset Management sold 324 Crinetics Pharmaceuticals shares in Q2 2021, an estimated $5K.
  • Panagora Asset Management first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Panagora Asset Management's Crinetics Pharmaceuticals position peaked at $5K in Q1 2021.
  • 83 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2021.

Based on Panagora Asset Management's 13F filing for Q2 2021, filed 11 Aug 2021.